BiotechTube

ABT-288 Low Dose + Placebo + ABT-288 High Dose

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cognitive Deficits in Schizophrenia

Conditions

Cognitive Deficits in Schizophrenia

Trial Timeline

Mar 1, 2010 → Jul 1, 2011

NCT ID
NCT01077700

About ABT-288 Low Dose + Placebo + ABT-288 High Dose

ABT-288 Low Dose + Placebo + ABT-288 High Dose is a phase 2 stage product being developed by AbbVie for Cognitive Deficits in Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01077700. Target conditions include Cognitive Deficits in Schizophrenia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01077700Phase 2Completed

Competing Products

20 competing products in Cognitive Deficits in Schizophrenia

See all competitors
ProductCompanyStageHype Score
Aricept (donepezil hydrochloride) + placeboEisaiApproved
85
DonepezilEisaiApproved
85
AriceptEisaiPhase 2
52
Donanemab + AducanumabEli LillyPhase 3
77
ABT-126 + PlaceboAbbViePhase 2
52
SDI-118 + PlaceboAbbViePhase 1
33
AZD5213 + AZD5213 + AZD5213AstraZenecaPhase 2
52
MK-8931MerckPhase 1
33
Nicotine patch + MK-4334 + Placebo patch + Placebo capsuleMerckPhase 1
33
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)MerckPhase 3
77
RivastigmineNovartisPhase 3
77
RivastigmineNovartisApproved
85
Exelon (rivastigmine) + PlaceboNovartisApproved
85
CanakinumabNovartisPhase 2
52
EvipleraGilead SciencesApproved
84
atorvastatinPfizerPre-clinical
22
bosutinibPfizerPhase 1
32
Aducanumab + PlaceboBiogenPhase 2
49
BIIB080 + BIIB080-matching placeboBiogenPhase 2
49
BIIB104BiogenPhase 2
49

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85